White Paper i Omnichannel Engagement: Why Isn’t Pharma There Yet? Learn More White Paper i Data-Driven Customer Journey Design Using Bayesian Network Methodology Learn More Roundtable i Pharma Omnichannel Trends In A Post-COVID World Learn More Report i HEOR Value Demonstration and Evidence Generation Challenges Learn More White Paper i Why The COVID-19 Recession Is Different And More Dangerous Than The Great Recession Learn More White Paper i What Analytical Techniques Should Pharma Companies Implement To Forecast COVID-19 Effects? Learn More White Paper i What Is At Stake For The Pharma Industry From The Upcoming 2020 Elections? Learn More White Paper i Will The Pharma Industry’s Response To COVID-19 Positively Affect Its Image? A Commentary Learn More White Paper i Effects Of A Resurgence In COVID-19 Cases On Future Pharmaceutical Business Planning Learn More White Paper i COVID-19 Recession Effects On Pharmaceutical-Related Patient Health Outcomes Learn More White Paper i Coronavirus Pandemic Effects On Incentive Compensation Learn More White Paper i How Will The Coronavirus Pandemic Affect The US Pharmaceutical Industry? Learn More White Paper i Can The Coronavirus Contagion Economically Infect The Global Pharmaceutical Industry? Learn More White Paper i Importation Of Drugs Is Back Again On The Pharma Public Policy Table – A Short Commentary Learn More White Paper i Pharma’s Bold And Potentially Risky New Cancer Drug R&D Portfolio Strategy Learn More White Paper i How Will The Next Great Recession Affect The US Pharma Industry? Learn More White Paper i Do Pharma Mergers And Acquisitions Improve R&D Productivity And Increase Shareholder Value? Learn More White Paper i Growing Attention Being Paid To Pharma Company Rebates And Discounts Learn More White Paper i Perspectives On Pharma Company Use Of Open Payments Data Learn More White Paper i Challenges And Opportunities To Commercialize Orphan Drugs For Rare Diseases In The US Learn More White Paper i Is The CVS-Aetna Merger A Pharma Industry Transformative Event? Learn More White Paper i How Will The 2018 Midterm Congressional Election Results Affect The US Pharma Industry? Learn More White Paper i Improve STAR Rating With Analytics Powered Therapy Adherence Strategy Learn More White Paper i Deploying K-Nearest Neighbor Modeling Methodologies For Real World Problems Learn More White Paper i The Pricing Challenge Of Pharma’s Shift To Specialty Medicines Learn More White Paper i Biosimilars In The US – Will They Deliver On The Promise? Learn More Article i Impact Of State Pharmacy Drug Product Selection Laws On Patient Brand – Generic Drug Utilization Learn More White Paper i The Changing Role Of Pharma Sales And Marketing In A Specialty Medicine Environment Learn More White Paper i The Relationship Between Drug Price Controls And Patient Health Outcomes Learn More White Paper i Patient Claims Versus EHR Data – How To Choose Between The Two? Learn More Blog i Is Biopharmaceutical Industry Drug Demand Becoming More Recession Sensitive? Learn More White Paper i Make US Pharma Great Again!? – Part 1 Learn More White Paper i Make US Pharma Great Again!? – Part 2 Learn More White Paper i Global Pharma Pricing and Market Effects of President Trump’s Proposed Policies Learn More White Paper i Designing Incentive Compensation Plans for Specialty Products Learn More White Paper i Pricing and Market Effects of Biosimilar Entry in the US Learn More White Paper i The Reasons for and Solutions to Chronic Drug Shortages in the United States Learn More White Paper i The Causes and Solutions of Chronic Drug Shortages in the United States Learn More
